Report Overview

The global nasal drug delivery market was valued at US$ 63.58 billion in 2021 and is expected to witness a CAGR of 6.1% during the forecast period from 2022 to 2030.

Market Fundamentals                                                                                          

Delivering local and systemic drugs using the nasal cavity (nose) as an administrative route is known as the nasal drug delivery system. This type of drug delivery system provides a wide range of advantages, such as a faster effect and a convenient method. It is an alternative method for the oral drug delivery system because rapid drug absorption via the nasal epithelium is possible due to its high permeability avoiding hepatic first-pass metabolism and membrane.

[53423232]

Market Dynamics

The nasal drug delivery market is a considerably vast industry. It is expected to show consistent growth during the forecast period. The development of the market can be attributed to the rising prevalence of asthma and COPD, growing patient preference, and increasing demands for nasal drug delivery systems among the population. Additionally, rising usage of self-administrative drug services, increasing technological advancements such as smart nasal drug delivery systems, and high accessibility ultimately boost the market expansion. However, inadequate knowledge of the nasal drug delivery system and problems related to over usage of nasal sprays can prove to be a significant challenge for market development.

Market Ecosystem

The global nasal drug delivery market has been analyzed from four perspectives: by type, application, distribution channel, and region. 

Nasal Drug Delivery Market by Type

[421312132]

Based on type, the global nasal drug delivery market has been segmented into the nebulizer, metered dose inhaler, and dry powder inhaler. Dry powder inhalers dominate the market with the largest revenue share. The growth of this segment can be attributed to various factors such as stability, the flexibility to give low or high doses, and its low sensitivity to microorganisms. On the other hand, metered dose inhalers are the second largest shareholder in the market. The growth of this segment can be attributed to its advantages, such as the multidose delivery capability, reduced loss of drug/dose, and provide convenience. Additionally, it can be used for pressurized metered doses, delivers a limited & specified drug amount, and does not require the pre-preparation of drugs.

Nasal Drug Delivery Market by Application

Based on the application, the global nasal drug delivery market has been segmented into asthma, chronic obstructive pulmonary disease (COPD), nasal congestion, rhinitis, and vaccination. COPD accounts for the largest share in the segment. The growing prevalence of COPD among the population is a prime cause for the growth of this segment. Risk factors include intensive smoking; long-term exposure to dust, fumes, and chemicals; a rare genetic condition called Alpha-1; and some childhood respiratory infections that may cause COPD. Thus, increasing cases of COPD proportionately increase the utilization of nasal drug systems/devices, thereby upsurging the overall market growth.

Nasal Drug Delivery Market by Distribution Channel

The nasal drug delivery market has been segmented based on distribution channels into hospitals, retail pharmacies, and online pharmacies. The hospital holds the largest revenue share in the market due to the high utilization rate because of growing respiratory disorders or illnesses. This segment attracts the largest patient footfall. While retail pharmacies are the second largest shareholder in the market due to the increasing prevalence of various respiratory diseases; thus, raising the consumer rate.

Nasal Drug Delivery Market by Region

Geographically, the nasal drug delivery market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America acquires high revenue shares in the market. Thus, the market growth can be attributed to various factors such as developed healthcare infrastructure, advanced technologies, and development in R&D activities. Additionally, increase in the cases of respiratory diseases and a high number of vaccinations and drug delivery devices. At the same time, Europe comes second in revenue share owing to the growing prevalence of infections, asthma, etc. The Asia Pacific is an emerging region in this market due to developing healthcare infrastructure, growing geriatric population, increasing vaccinations among the population, and many more. Furthermore, growing R&D activities and enhancing healthcare expenditure further contribute to the growth of the nasal drug delivery market.

Competitive Landscape

Some prominent players operating in the global nasal drug delivery market are: 

• Gofire Inc.
• 3M Co.
• Teva Pharmaceutical Industries Ltd.
• Nemera France SAS
• AptarGroup Inc.
• H&T Presspart Manufacturing Ltd.
• Consort Medical Plc.
• Vectura Group Limited
• Merck & Co. Inc.
• Johnson & Johnson Services Inc.
• GSK plc.
• Pfizer Inc.

Strategic Developments

• In March 2021, Aptar Pharma, and Noble collaborated with dne pharma, to provide a nasal drug delivery system for treating opioid overdose. This collaboration was established to enhance Aptar Pharma’s premium product portfolio in drug delivery.
• In Feb 2021, Nanoform Finland collaborated with Herantis, and  signed a Biologics Proof of Concept Agreement to develop nasal drug delivery solutions to the brain of Herantis’ CDNF therapies for Parkinson’s disease using Nanoform’s proprietary biological nanoparticle technology. 
• In June 2020, GSK (GlaxoSmithKline) introduced a saline-based nasal spray in its Piri range to enhance the product pipeline and market revenue. This spray can treat allergies and fever by clearing the nasal cavity. 

Frequently Asked Questions About This Report